209 related articles for article (PubMed ID: 36796671)
21. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Mann DL; Givertz MM; Vader JM; Starling RC; Shah P; McNulty SE; Anstrom KJ; Margulies KB; Kiernan MS; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; DeVore AD; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JAMA Cardiol; 2022 Jan; 7(1):17-25. PubMed ID: 34730769
[TBL] [Abstract][Full Text] [Related]
22. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial.
Gori M; Senni M; Claggett B; Liu J; Maggioni AP; Zile M; Prescott MF; Van Veldhuisen DJ; Zannad F; Pieske B; Lam CSP; Rouleau J; Jhund P; Packer M; Pfeffer MA; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
JACC Heart Fail; 2021 Sep; 9(9):627-635. PubMed ID: 34246603
[TBL] [Abstract][Full Text] [Related]
23. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
Vaduganathan M; Claggett BL; Desai AS; Anker SD; Perrone SV; Janssens S; Milicic D; Arango JL; Packer M; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Jan; 75(3):245-254. PubMed ID: 31726194
[TBL] [Abstract][Full Text] [Related]
24. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure.
Feng Z; Wang X; Zhang L; Apaer R; Xu L; Ma J; Li X; Che H; Tang B; Xiong Y; Xia Y; Xiao J; Su X; Wang Y; Dou X; Chen J; Mei L; Xue Z; Kong Y; Li S; Zhang H; Lin T; Wen F; Fu X; Tao Y; Fu L; Li Z; Huang R; Ye Z; He C; Shi W; Liang X; Ke G; Liu S
Blood Purif; 2022; 51(3):270-279. PubMed ID: 34753147
[TBL] [Abstract][Full Text] [Related]
26. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
[TBL] [Abstract][Full Text] [Related]
27. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Vaduganathan M; Cunningham JW; Claggett BL; Causland FM; Barkoudah E; Finn P; Zannad F; Pfeffer MA; Rizkala AR; Sabarwal S; McMurray JJV; Solomon S; Desai AS
JACC Heart Fail; 2021 May; 9(5):374-382. PubMed ID: 33839075
[TBL] [Abstract][Full Text] [Related]
28. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study.
Omar AMS; Murphy S; Felker GM; Piña I; Butler J; Liu Y; Mohebi R; Bhatia K; Ward JH; Williamson KM; Solomon SD; Januzzi JL; Contreras J
J Card Fail; 2024 May; 30(5):653-665. PubMed ID: 37816446
[TBL] [Abstract][Full Text] [Related]
29. Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
Myhre PL; Liu Y; Kulac IJ; Claggett BL; Prescott MF; Felker GM; Butler J; Piña IL; Rouleau JL; Zile MR; McMurray JJV; Ward JH; Solomon SD; Januzzi JL
Eur J Heart Fail; 2023 Aug; 25(8):1396-1405. PubMed ID: 37401523
[TBL] [Abstract][Full Text] [Related]
30. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
[TBL] [Abstract][Full Text] [Related]
31. Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.
Savarese G; Hage C; Benson L; Schrage B; Thorvaldsen T; Lundberg A; Fudim M; Linde C; Dahlström U; Rosano GMC; Lund LH
J Intern Med; 2021 Mar; 289(3):369-384. PubMed ID: 32776357
[TBL] [Abstract][Full Text] [Related]
32. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
33. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
Foà A; Vaduganathan M; Claggett BL; Pabon MA; Lu H; Pfeffer MA; Packer M; Vardeny O; Rouleau JL; Lefkowitz M; Mentz RJ; Jhund PS; Desai AS; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2024 May; 83(18):1731-1739. PubMed ID: 38537919
[TBL] [Abstract][Full Text] [Related]
34. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
[TBL] [Abstract][Full Text] [Related]
36. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
Selvaraj S; Claggett BL; Böhm M; Anker SD; Vaduganathan M; Zannad F; Pieske B; Lam CSP; Anand IS; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2020 Apr; 75(14):1644-1656. PubMed ID: 32192799
[TBL] [Abstract][Full Text] [Related]
37. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
Albert NM; Swindle JP; Buysman EK; Chang C
J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
[TBL] [Abstract][Full Text] [Related]
38. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan.
Butt JH; McDowell K; Kondo T; Desai AS; Lefkowitz MP; Packer M; Petrie MC; Pfeffer MA; Rouleau JL; Vaduganathan M; Zile MR; Jhund PS; Køber L; Solomon S; McMurray JJV
ESC Heart Fail; 2024 Feb; 11(1):65-77. PubMed ID: 37813587
[TBL] [Abstract][Full Text] [Related]
39. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
[TBL] [Abstract][Full Text] [Related]
40. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
Piña IL; Camacho A; Ibrahim NE; Felker GM; Butler J; Maisel AS; Prescott MF; Williamson KM; Claggett BL; Desai AS; Solomon SD; Januzzi JL;
JACC Heart Fail; 2021 Jan; 9(1):42-51. PubMed ID: 33189630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
